Romidepsin for cutaneous T-cell lymphoma Full Text
Clinical Cancer Research, 05/02/2012
Clinical Article
Prince HM et al. – Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side effect profile.



